Checkpoint Therapeutics (CKPT) News Today $3.13 -0.05 (-1.57%) Closing price 04:00 PM EasternExtended Trading$3.24 +0.12 (+3.67%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 9,233 SharesFebruary 12, 2025 | insidertrades.comCheckpoint Therapeutics CEO sells $64,027 in stockFebruary 12, 2025 | msn.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $31,484.53 in StockCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CEO James F. Oliviero III sold 9,233 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $3.41, for a total transaction of $31,484.53. Following the completion of the sale, the chief executive officer now directly owns 3,785,350 shares in the company, valued at approximately $12,908,043.50. This trade represents a 0.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 11, 2025 | marketbeat.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $32,542.65 in StockCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CEO James F. Oliviero III sold 10,331 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $3.15, for a total transaction of $32,542.65. Following the transaction, the chief executive officer now owns 3,775,019 shares in the company, valued at $11,891,309.85. The trade was a 0.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.February 11, 2025 | marketbeat.comInsider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells $271,983.70 in StockFebruary 8, 2025 | insidertrades.comCheckpoint Therapeutics CFO sells shares worth $271,983February 8, 2025 | msn.comInsider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 74,110 Shares of StockCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CFO William Garrett Gray sold 74,110 shares of the firm's stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total value of $271,983.70. Following the completion of the transaction, the chief financial officer now owns 1,458,644 shares in the company, valued at $5,353,223.48. This represents a 4.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 7, 2025 | marketbeat.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) stock most popular amongst individual investors who own 56%, while public companies hold 14%February 3, 2025 | finance.yahoo.comCheckpoint Therapeutics, Inc. Common Stock (CKPT) Institutional HoldingsFebruary 2, 2025 | nasdaq.comShort Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Increases By 17.5%Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 8,000,000 shares, a growth of 17.5% from the December 15th total of 6,810,000 shares. Based on an average daily volume of 1,410,000 shares, the days-to-cover ratio is currently 5.7 days. Approximately 21.1% of the company's stock are sold short.January 19, 2025 | marketbeat.comCheckpoint Therapeutics initiated with a Buy at D. Boral CapitalJanuary 14, 2025 | markets.businessinsider.comD. Boral Capital Initiates Coverage of Checkpoint Therapeutics (CKPT) with Buy RecommendationJanuary 14, 2025 | msn.comCheckpoint Therapeutics (NASDAQ:CKPT) Now Covered by D. Boral CapitalD. Boral Capital assumed coverage on Checkpoint Therapeutics in a research note on Monday. They issued a "buy" rating and a $9.00 price objective on the stock.January 13, 2025 | marketbeat.comCheckpoint Therapeutics Signs Executive Agreement with CFOJanuary 10, 2025 | tipranks.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 220,230 SharesDecember 21, 2024 | insidertrades.comJames F. Oliviero III Sells 220,230 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) StockCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CEO James F. Oliviero III sold 220,230 shares of the business's stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $3.38, for a total transaction of $744,377.40. Following the completion of the transaction, the chief executive officer now owns 3,194,583 shares of the company's stock, valued at approximately $10,797,690.54. This trade represents a 6.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.December 20, 2024 | marketbeat.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 268,432 SharesCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CFO William Garrett Gray sold 268,432 shares of the business's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total value of $1,076,412.32. Following the completion of the transaction, the chief financial officer now directly owns 1,032,754 shares of the company's stock, valued at $4,141,343.54. The trade was a 20.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.December 20, 2024 | marketbeat.comCheckpoint Therapeutics: Updating My Strategy After Unloxcyt's ApprovalDecember 18, 2024 | seekingalpha.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Up 9.0% in NovemberCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 6,570,000 shares, a growth of 9.0% from the November 15th total of 6,030,000 shares. Currently, 16.2% of the shares of the company are sold short. Based on an average trading volume of 807,000 shares, the short-interest ratio is currently 8.1 days.December 16, 2024 | marketbeat.comCheckpoint Therapeutics Upgraded to Buy Following FDA Approval and Increased Price TargetDecember 16, 2024 | markets.businessinsider.comCheckpoint Therapeutics Sees Unusually High Options Volume (NASDAQ:CKPT)Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the recipient of unusually large options trading on Monday. Stock traders bought 7,866 call options on the company. This represents an increase of approximately 1,998% compared to the typical daily volume of 375 call options.December 16, 2024 | marketbeat.comLake Street Capital Forecasts Strong Price Appreciation for Checkpoint Therapeutics (NASDAQ:CKPT) StockLake Street Capital increased their price target on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a "buy" rating in a research report on Monday.December 16, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Checkpoint Therapeutics (NASDAQ:CKPT)HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Monday.December 16, 2024 | marketbeat.comCheckpoint Therapeutics Gets Its First FDA ApprovalDecember 15, 2024 | marketwatch.comCheckpoint Therapeutics, Inc: Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl)December 14, 2024 | finanznachrichten.deCheckpoint Therapeutics Announces FDA Approval of UNLOXCYT(TM) (cosibelimab-ipdl)December 14, 2024 | stockhouse.comCheckpoint Therapeutics' Shares Rise After Securing First FDA ApprovalDecember 14, 2024 | marketwatch.comCheckpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)December 14, 2024 | markets.businessinsider.comUS FDA approves Checkpoint's skin cancer drugDecember 14, 2024 | reuters.comCheckpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)December 13, 2024 | globenewswire.comBuy Rating for Checkpoint Therapeutics: Anticipated Approval of Cosibelimab and Strategic Growth OpportunitiesDecember 7, 2024 | markets.businessinsider.comFY2024 Earnings Forecast for CKPT Issued By HC WainwrightCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Free Report) - Equities research analysts at HC Wainwright cut their FY2024 earnings per share estimates for shares of Checkpoint Therapeutics in a research note issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that tNovember 18, 2024 | marketbeat.comCheckpoint Therapeutics Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023)November 16, 2024 | uk.finance.yahoo.comCheckpoint Therapeutics, Inc: Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate UpdatesNovember 14, 2024 | finanznachrichten.deOptimistic Buy Rating for Checkpoint Therapeutics Driven by Strong Financial Position and Strategic CollaborationsNovember 14, 2024 | markets.businessinsider.comCheckpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA DateNovember 14, 2024 | seekingalpha.comWest Virginia State Police to hold DUI Checkpoint in Mercer CountyNovember 14, 2024 | msn.comCheckpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate UpdatesNovember 12, 2024 | globenewswire.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) Sees Large Increase in Short InterestCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 4,610,000 shares, a growth of 5.3% from the September 30th total of 4,380,000 shares. Based on an average daily trading volume, of 459,900 shares, the days-to-cover ratio is presently 10.0 days. Approximately 12.3% of the company's shares are sold short.October 31, 2024 | marketbeat.comOvercoming Resistance to Checkpoint Inhibitor Cancer TherapyOctober 25, 2024 | forbes.comCheckpoint Therapeutics (NASDAQ:CKPT) Stock, Short Interest ReportOctober 8, 2024 | benzinga.comBodycam Footage Shows Influencer Therapist's 2023 DUI Arrest At NJ Town's Sobriety CheckpointOctober 4, 2024 | msn.comMetabolic reprogramming of T cells may enhance checkpoint inhibitor therapySeptember 26, 2024 | msn.comBuy Rating Justified by Promising Efficacy of Checkpoint’s Cosibelimab in Clinical TrialsSeptember 17, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Checkpoint Therapeutics (NASDAQ:CKPT)HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday.September 16, 2024 | marketbeat.comCheckpoint Therapeutics Presents Cosibelimab Longer-Term Results In Advanced CSCCSeptember 16, 2024 | markets.businessinsider.comCheckpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024September 16, 2024 | globenewswire.comCharlotte Airport Checkpoint C closing Thursday for constructionSeptember 6, 2024 | yahoo.comCheckpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comCLT Airport Checkpoint C closing, new American counters open in next step of expansionSeptember 4, 2024 | yahoo.com Get Checkpoint Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. Email Address CKPT Media Mentions By Week CKPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CKPT News Sentiment▼0.000.60▲Average Medical News Sentiment CKPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CKPT Articles This Week▼03▲CKPT Articles Average Week Get Checkpoint Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AnaptysBio News Today Kura Oncology News Today CorMedix News Today Arbutus Biopharma News Today Pharming Group News Today Immatics News Today ORIC Pharmaceuticals News Today Rapport Therapeutics News Today Septerna News Today Precigen News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CKPT) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CKPT Stock Alerts